Evido Health

🕵️♂️ Uncovering SLD’s Prevalence   Did you know the prevalence of steatotic liver disease (SLD) is severely underestimated? Here’s why: ➡️ SLD is mostly asymptomatic until it’s too late, making early diagnosis difficult. ➡️ Current diagnosis codes don’t effectively track SLD diagnoses.   This creates a major gap in understanding the real burden of SLD, which is critical for: 1️⃣ Engaging payers to shape informed policies. 2️⃣ Raising awareness among physicians and patients through data-driven campaigns.   LiverPRO bridges this gap with a concrete approach: ✅ It adapts to missing data, providing reliable local estimations of SLD prevalence. ✅ It uses routine blood samples for easy, scalable implementation. With LiverPRO, we’re creating a foundation for informed conversations and actionable insights.   Imagine the impact of understanding SLD prevalence in your community, grounded in real data.   📩 Interested? Connect with Klaus to learn more! Stay tuned for the next post in our series: 🍻 Sip or Skip? Alcohol vs. metabolic risk factors Katrine Prier Lindvig | Taus Holtug | Maja Thiele | Aleksander Krag | Søren Boll Overgaard | Andreas Melgaard Sand, PhD | Klaus Møller | Tina Travnik | Florian Kirstein

Join Us at The Liver Meeting in San Diego! 🇺🇸 🩺 We’re excited to participate in this year’s Liver Meeting, hosted by the American Association for the Study of Liver Diseases (AASLD), from November 16-19 in San Diego, CA! Let’s connect and talk about the future of data-driven diagnostics in steatotic liver disease. If you’re interested, we’d love to meet you there! 📅 Reach out to Katrine Prier Lindvig or Klaus Møller to schedule a chat. See you in San Diego!

💉 Pharma’s New Ally: LiverPRO for recruitment Recruiting patients in clinical trials for indications in liver disease such as NASH and MASH is tough: 👉 Screen failure rates are as high as 90%. 👉 Slow enrolment due to the asymptomatic nature of liver disease, making it difficult to find eligible study participants.   This is a major pain for the liver field where study enrolment is especially lengthy and resource-intensive, leading to significant delays in the time-to-market for helpful drugs and impact for patients in need.   As a certified fibrosis marker that can be sampled almost anywhere, LiverPRO makes patient recruitment easier and faster. For clinical trials, this means: ✅ Reduced screen failure rates ✅ Increased enrolment rates ✅ Larger pool of eligible patients The stats don’t lie. At this year’s EASL Congress, our collaboration with Naim Alkhouri, and Arizona Liver Health showed a 108% improvement in enrolment rates and 40% reduction in false negatives when using LiverPRO for trial screening.   Evido’s mission is to be pharma’s ally and help speed up trials to deliver impactful treatments faster.   If you’re in clinical recruitment, or just curious about how LiverPRO could help with your next trial, reach out to Klaus for more details.   Stay tuned for the next post in our series: 🕵️♂️ Uncovering SLD’s Prevalence Katrine Prier Lindvig | Taus Holtug | Maja Thiele | Aleksander Krag | Søren Boll Overgaard | Andreas Melgaard Sand, PhD | Klaus Møller | Tina Travnik | Florian Kirstein

👩⚕️ The Patient Perspective: what’s in it for me? Did you know that: ❗ Only 5% of patients are actually aware that they have steatotic liver disease (SLD). ❗ Typically, these patients visit their general practitioner regularly, often for conditions like type 2 diabetes, obesity, and alcohol overuse. But there’s no routine test available for general practitioners to check for liver health. ❗ For the 95% of patients who consequentially don’t know about their liver health, everything seems fine until years later, when they must go to hospital with severe complications. This pattern results in 75% of patients with SLD being diagnosed too late, when no intervention can help and the only solution is a liver transplant. That statistic is simply too large to be left alone. The mission of LiverPRO is to address this unfortunate statistic. It does so by: ➡️ Providing accurate detection of SLD where patients actually are → in the offices of general practitioners, outside of specialist care. ➡️ Leveraging existing patient funnels by providing the assessment as part of routine check-ups such as those living with type 2 diabetes receive. ➡️ Making it cost-effective to enable high-volume testing where patients already are. LiverPRO is the first diagnostic tool in this liver space that can achieve this. That is why patients should care. Stay tuned for the next post in our series: 💉 Pharma’s New Ally: LiverPRO for recruitment. Katrine Prier Lindvig | Taus Holtug | Maja Thiele | Aleksander Krag | Søren Boll Overgaard | Andreas Melgaard Sand, PhD | Klaus Møller | Tina Travnik | Florian Kirstein

💻 LiverPRO in action: unlocking new clinical insights from existing healthcare data Liver disease silently affects millions, but LiverPRO is here to change that. LiverPRO is a game changing CE-certified, data-driven clinical platform designed to detect liver fibrosis before it's too late. Using standard blood tests and advanced algorithms, it accurately predicts liver fibrosis and classify patients with a 93% accuracy. It provides personalized clinical recommendations, empowering general practitioners to make better informed diagnoses. LiverPRO is designed to address a crucial gap by supporting millions of individuals that go undiagnosed of a chronic liver disease due to ineffective tools in primary care. LiverPRO is the first of its kind solution that bringes in-depth liver insights right to your family doctor’s office, enabling early detection when the disease is still reversible. This is liver health redefined—accessible, efficient, and empowering. Here’s why LiverPRO stands out: ▶ 41% improvement in correctly classified patients compared to standard of care ▶ 73% reduction in mean cost per patient compared to the standard of care pathway ▶ State of the art diagnostic and prognostic performance for a first-line test ▶ Validated in more than 500,000 patients ▶ CE-certified IVDR class-b, thereby approved for clinical implementation across Europe By seamlessly integrating into existing healthcare IT infrastructure, LiverPRO becomes the first-ever product to provide minimal disruption for clinics while ensuring timely detection of steatotic liver disease. This improves patient outcomes, reduces unnecessary referrals, and alleviates the burden on secondary care. Stay tuned for the next post in our series: 💡 The patient perspective: what’s in it for me? Katrine Prier Lindvig | Maja Thiele | Aleksander Krag | Søren Boll Overgaard | Andreas Melgaard Sand, PhD | Klaus Møller | Taus Holtug | Tina Travnik | Florian Kirstein

📊 Liver Disease in Numbers: The Silent Pandemic Did you know that steatotic liver disease (SLD) is quietly affecting millions, and most don’t even know it? 🩺 The stats are shocking: ▶ 1 in 3 people are already in the first stage of liver disease—and they’re completely unaware. ▶ 75% of end-stage liver disease cases are diagnosed too late, leaving limited treatment options. ▶ It’s the 2nd most frequent cause of lost working years in Europe and the US, as end-stage cirrhosis affects individuals aged 40 to 65 on average— that’s 18 years earlier than strokes or lung cancer. ▶ SLD causes more than 1 million deaths annually worldwide, making it comparable to diabetes. 💰 And it’s not just about health. This silent crisis is estimated to cost Europe €175 billion a year in total societal costs—that’s 5-6 times more than what’s directly spent on diagnosis and treatment! Why is this happening? ▶ Late diagnoses lead to end-stage progression. Here, the disease is no longer reversible, and expensive procedures to treat complications drive huge costs. ▶ Early patient detection is limited by current tests in primary care, which only present an accuracy of 53-65%, missing the majority of people with this hidden disease. As a result, direct medical costs for SLD are estimated to be €35 billion in Europe and €95 billion in the US, spent mainly on treating complications for terminal end-stage patients - without the opportunity to detect patients while it is still reversible. 💡 Evido is founded to specifically change this. Our solution? LiverPRO — a novel medical software that provide cost efficient detection of patients before it is too late. More on this later. 📄 Interested in diving more in to the numbers? Check out our white paper: “The price tag of a hidden global liver pandemic”. Find the link in the comments. Coming up next in the series: 💻 "LiverPRO in Action: More Than Just Software" Discover what LiverPRO really does and why it’s more than just code. Taus Holtug Katrine Prier Lindvig Klaus Møller Søren Boll Overgaard Andreas Melgaard Sand, PhD Maja Thiele Aleksander Krag Florian Kirstein Tina Travnik #LiverDisease #SLD #EvidoHealth #LiverPro #HealthcareInnovation #PreventiveHealth #PublicHealth #LiverHealth #MedicalTechnology #HealthcareCosts #PatientAwareness

🔎Uncovering Steatotic Liver Disease: This April, we achieved a major milestone with the regulatory approval of LiverPRO, our medical device software. Developed over several years and grounded in extensive clinical research, LiverPRO was designed with one clear goal: to change the course for millions of patients who go unnoticed until it’s too late. Now, we want to shed some light on the liver space, reintroduce LiverPRO, and discuss the critical challenges we must address. We’ll do this in a series of posts, starting with the big WHY? Why should you care? Have you never heard of Steatotic Liver Disease (SLD)? You’re not alone—but that’s exactly the problem. Steatotic Liver Disease (SLD) is often called a silent killer—and for good reason. It's responsible for 1 million deaths each year, with 75% of cases diagnosed too late. Key risk factors for SLD are type 2 diabetes, obesity, and excessive alcohol intake. All of these factors continue to rise and have made SLD a global health challenge that we can no longer ignore. The challenge? 🕵️ The real danger lies in its invisibility. Early symptoms are subtle—or absent entirely—making detection almost impossible without the right tools. By the time it's caught, SLD often progresses to severe cirrhosis and liver cancer. The solution? 💡 Experts agree: We need new ways to screen patients early, before symptoms appear. The key is integrating cost-effective, data-driven diagnostics outside of specialist care, giving doctors the ability to detect SLD early, manage it effectively, and prevent further liver damage. Without early detection, countless people will remain unaware until it's too late. The time for change is now—we have the tools, the data, and the urgency to act. Thanks to our CE certification, LiverPRO is one of the few solutions ready to close this gap, bringing tremendous benefits to patients, healthcare professionals and our healthcare systems. Stay tuned as we explore the liver health landscape and demonstrate how LiverPRO is making a difference. Coming up next in the series: 📊 "Liver Disease in Numbers" Breaking down chronic liver disease stats: the shocking figures everyone should know. Taus Holtug Katrine Prier Lindvig Klaus Møller Søren Boll Overgaard Andreas Melgaard Sand, PhD Maja Thiele Aleksander Krag Florian Kirstein Tina Travnik #EvidoHealth #CE #LiverDisease #SLD #LiverPRO

New article feature! Last week, our scientific cofounders, Maja Thiele and Aleksander Krag, along with our CSO and cofounder, Katrine Prier Lindvig, featured in an article by Dansk Selskab for Biokemi to spread the word about the future of diagnostics in the liver space. 👩🔬👨🔬 Naturally, LiverPRO is featured, standing out as a CE-certified solution that can ensure robust, efficient, and scalable detection of liver fibrosis outside of specialist care. We are proud to be in the forefront of this movement and to provide a solution that creates real benefits for patients in need. Check out the article for more details (unfortunately only in Danish): https://lnkd.in/dD8aENKG (pages 18-21) #LiverHealth #HealthcareInnovation #FibrosisTesting #EvidoHealth Taus Holtug, Katrine Prier Lindvig, Søren Boll Overgaard, Klaus Møller, Maja Thiele, Aleksander Krag, Florian Kirstein, Tina Travnik

Meet Andreas - Our Lead Machine Learning Specialist! Andreas Melgaard Sand, PhD is our lead machine learning specialist, driving Evido’s product development and unlocking new possibilities in medical diagnostics. Get to know our master machine learning expert below: Q: Why Evido? A: I chose Evido because of my deep interest in machine learning and the development of medical device software. The opportunity to apply machine learning in a way that genuinely impacts patients' lives is incredibly motivating. Moreover, the team at Evido is highly skilled, and the company's strong financial foundation—already generating revenue at such an early stage—offers an exciting and stable environment for growth. Q: What sparked your interest in machine learning in the diagnostic field? A: I've been passionate about machine learning since my master's and PhD studies in computer science. The power of machine learning lies in its ability to uncover patterns in data that are often (almost) impossible to express using traditional algorithms. While many machine learning applications focus on automating everyday tasks to improve efficiency, its impact in the diagnostic field is far more profound. Machine learning can often outperform human clinicians in accuracy, helping to free up essential resources and enabling healthcare professionals to focus on the tasks that matter most. Q: What do you do when you’re not changing the paradigm around chronic liver disease? A: In my free time, I enjoy spending time with my wife and children. I’m also an avid mountain biker and love riding the trails around Himmelbjerget, and I volunteer as a CrossFit instructor at the local CrossFit box. Q: What has been the most exciting part of your journey with Evido? A: The most exciting part of my journey with Evido has been getting to know all the inspiring people here. The passion, knowledge, and collaboration within the team have made it a truly exciting and rewarding experience. #MachineLearning #MedTech #EvidoHealth Taus Holtug, Katrine Prier Lindvig, Søren Boll Overgaard, Klaus Møller, Maja Thiele, Aleksander Krag, Florian Kirstein, Tina Travnik

Meet Tina - Our Business Development Associate at Evido! As our business development associate, Tina Travnik leverages her biology background to explore the business side of medtech at Evido, tackling a variety of tasks that bridge science and strategy. Get to know her a little better below: Q: Why Evido? A: As someone with a biology background, I’m always drawn to a holistic approach to health. What really resonates with me about Evido is its focus on preventative healthcare. Instead of just addressing symptoms, we help identify the root cause, which aligns perfectly with my core values and interests. Plus, it’s incredibly exciting to be part of a company leading the charge in uncovering a hidden, often overlooked disease. Q: What sparked your interest in the business development field? A: While my earlier work was centered around research, I soon realized I was more interested in seeing how that research could evolve into products that genuinely help people. Business development sits at this pivotal point—connecting innovation with impact. Working in medtech business development at Evido lets me blend my scientific knowledge with my growing understanding of how businesses operate, grow, and innovate. It’s a fantastic complement to my studies, and I’m loving every minute of putting theory into practice. Q: What do you do when you’re not changing the paradigm around chronic liver disease? A: Alongside my role at Evido, I’m pursuing a master's degree in Business Administration and Bioentrepreneurship at Copenhagen Business School. Outside of that, I’m a big fan of meeting up with friends to explore Copenhagen’s incredible food scene, embracing the city’s sporty culture, and cozying up in a quaint little coffee shop. Q: What has been the most exciting part of your journey with Evido? A: I joined Evido at a really exciting time, just as we’re expanding and securing major clients. Every day brings something new, and I’m so lucky to work alongside such a smart, fun, and supportive team. The variety of responsibilities I have allows me to learn an incredible amount, and I genuinely feel like I’m contributing to something meaningful. Taus Holtug, Katrine Prier Lindvig, Søren Boll Overgaard, Klaus Møller, Andreas Melgaard Sand, PhD, Maja Thiele, Aleksander Krag #BusinessDevelopment #MedTech #PreventativeHealthcare #EvidoHealth